Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo-Implications for biomarker discovery

PLoS One. 2020 Aug 19;15(8):e0236439. doi: 10.1371/journal.pone.0236439. eCollection 2020.

Abstract

Extracellular vesicles (EVs) in human blood are a potential source of biomarkers. To which extent anticoagulation affects their concentration, cellular origin and protein composition is largely unexplored. To study this, blood from 23 healthy subjects was collected in acid citrate dextrose (ACD), citrate or EDTA, or without anticoagulation to obtain serum. EVs were isolated by ultracentrifugation or by size-exclusion chromatography (SEC) for fluorescence-SEC. EVs were analyzed by micro flow cytometry, NTA, TEM, Western blot, and protein mass spectrometry. The plasma EV concentration was unaffected by anticoagulants, but serum contained more platelet EVs. The protein composition of plasma EVs differed between anticoagulants, and between plasma and serum. Comparison to other studies further revealed that the shared EV protein composition resembles the "protein corona" of synthetic nanoparticles incubated in plasma or serum. In conclusion, we have validated a higher concentration of platelet EVs in serum than plasma by contemporary EV methods. Anticoagulation should be carefully described (i) to enable study comparison, (ii) to utilize available sample cohorts, and (iii) when preparing/selecting biobank samples. Further, the similarity of the EV protein corona and that of nanoparticles implicates that EVs carry both intravesicular and extravesicular cargo, which will expand their applicability for biomarker discovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood*
  • Blood Platelets / chemistry
  • Blood Proteins / genetics
  • Blood Proteins / isolation & purification*
  • Extracellular Vesicles / genetics*
  • Female
  • Flow Cytometry / methods
  • Healthy Volunteers
  • Humans
  • Male
  • Mass Spectrometry / methods
  • Middle Aged
  • Proteome / genetics*

Substances

  • Biomarkers
  • Blood Proteins
  • Proteome

Grants and funding

This study has been supported by the Academy of Finland (grants 287089 (PRMS) and 315227(M. Palviainen)), Magnus Ehrnrooth Foundation (PRMS), Medicinska Understödsföreningen Liv och Hälsa rf. (PRMS) and by the National Research, Development and Innovation Office NKFIH, Hungary (ZV, grants PD 121326 and NVKP_16-1-2016-0007). ZV was supported by the János Bolyai Research Fellowship. DK was supported by the ÚNKP-19-3 New National Excellence Program of the Ministry for Innovation and Technology.